Devices for distal protection during percutaneous coronary revascularization

Circulation

Volumn 113, Issue 22, 2006, Pages 2651-2656

  Mauri, Laura ^a,b,e   Rogers, Campbell ^a,d,e   Baim, Donald S ^a,b,c,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^c Center for Integration of Medicine and Innovative Technology   (United States)

^d HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Coronary intervention; Revascularization; Saphenous vein graft; Stents

Indexed keywords

ATHEROSCLEROSIS; DEVICE; EMBOLISM; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; PRIORITY JOURNAL; REVIEW; APPARATUS, EQUIPMENT AND SUPPLIES; CORONARY ARTERY DISEASE; CORONARY BLOOD VESSEL; HEART CATHETERIZATION; INSTRUMENTATION; METHODOLOGY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROSTHESES AND ORTHOSES; STENT;

ANGIOPLASTY, BALLOON; ATHEROSCLEROSIS; CORONARY DISEASE; CORONARY VESSELS; EMBOLISM; EQUIPMENT AND SUPPLIES; HEART CATHETERIZATION; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROSTHESES AND IMPLANTS; STENTS;

EID: 33745129383     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.551770     Document Type: Review

References (25)

1. Mak KH, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. Am J Cardiol. 1997;80:985-988.
2. Ellis SG, Lincoff AM, Miller D, Tcheng JE, Kleiman NS, Kereiakes D, Califf R, Topol EJ. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade. J Am Coll Cardiol. 1998;32:1619-1623.
3. Roffi M, Mukherjee D, Chew DP, Bhatt DL, Cho L, Robbins MA, Ziada KM, Brennan DM, Ellis SG, Topol EJ. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials. Circulation. 2002;106:3063-3067.
4. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, Mishkel GJ, Bajwa TK, Whitlow P, Strickman NE, Jaff MR, Popma JJ, Snead DB, Cutlip DE, Firth BG, Ouriel K; Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy Investigators. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med. 2004;351:1493-1501.
5. Baim DS, Wahr D, George B, Leon MB, Greenberg J, Cutlip DE, Kaya U, Popma JJ, Ho KK, Kuntz, RE; Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation. 2002;105:1285-1290.
6. Quan VH, Huynh R, Seifert PA, Kuchela A, Chen WH, Sutsch G, Eisenhauer AC, Rogers C. Morphometric analysis of particulate debris extracted by four different embolic protection devices from coronary arteries, aortocoronary saphenous vein conduits, and carotid arteries. Am J Cardiol. 2005;95:1415-1419.
7. Giugliano GR, Kuntz RE, Popma JJ, Cutlip DE, Baim DS; Saphenous vein graft Angioplasty Free of Emboli Randomized (SAFER) Trial Investigators. Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device. Am J Cardiol. 2005;95:173-177.
8. Cohen DJ, Murphy SA, Baim DS, Lavelle TA, Berezin RH, Cutlip DE, Ho KK, Kuntz RE; SAFER Trial Investigators. Cost-effectiveness of distal embolic protection for patients undergoing percutaneous intervention of saphenous vein bypass grafts: results from the SAFER trial. J Am Coll Cardiol. 2004;44:1801-1808.
9. Carrozza JP Jr, Mumma M, Breall JA, Fernandez A, Heyman E, Metzger C; PRIDE Study Investigators. Randomized evaluation of the TriActiv balloon-protection flush and extraction system for the treatment of saphenous vein graft disease. J Am Coll Cardiol. 2005;46:1677-1683.
10. Limbruno U, De Caterina R. EMERALD, AIMI, and PROMISE: is there still a potential for embolic protection in primary PCI? Eur Heart J. 2006;27:1139-1145.
11. Gick M, Jander N, Bestehorn HP, Kienzle RP, Ferenc M, Werner K, Comberg T, Pietz K, Zohlnhofer D, Bassignana V, Buettner HJ, Neumann FJ. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myocardial infarction with and without ST-segment elevation. Circulation. 2005;112:1462-1469.
12. Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, Turco M, Schultheiss HP, Dulas D, Rutherford BD, Antoniucci D, Krucoff MW, Gibbons RJ, Jones D, Lansky AJ, Mehran R; Enhanced Myocardial Efficacy and Recovery by Aspiration of Liberated Debris (EMERALD) Investigators. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA. 2005;293:1063-1072.
13. Kuntz RE, Rogers C, Baim DS. Percutaneous coronary intervention-induced emboli during primary PCI for STEMI: too little, too much, or too late? Am Heart J. 2005;150:4-6.
14. Rogers C, Huynh R, Seifert PA, Chevalier B, Schofer J, Edelman ER, Toegel G, Kuchela A, Woupio A, Kuntz RE, Macon ND. Embolic protection with filtering or occlusion balloons during saphenous vein graft stenting retrieves identical volumes and sizes of particulate debris. Circulation. 2004;109:1735-1740.
15. Hori M, Inoue M, Kitakaze M, Koretsune Y, Iwai K, Tamai J, Ito H, Kitabatake A, Sato T, Kamada T. Role of adenosine in hyperemic response of coronary blood flow in microembolization. Am J Physiol. 1986;250:H509-H518.
16. Stone GW, Rogers C, Hermiller J, Feldman R, Hall P, Haber R, Masud A, Cambier P, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA; FilterWire EX Randomized Evaluation Investigators. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. Circulation. 2003;108:548-553.
17. Holmes DJ. CAPTIVE: a prospective randomized controlled trial of distal protection with the third-generation Mednova Emboshield compared to the GuardWire or FilterWire. Paper presented at: Transcatheter Cardiovascular Therapeutics; September 28, 2004; Washington, DC.
18. Rogers C. A prospective randomized comparison of proximal and distal protection in patients with diseased saphenous vein grafts [abstract]. Presented at Transcatheter Cardiovascular Therapeutics, October 2005.
19. Blackman DJ, Choudhury RP, Banning AP, Channon KM. Failure of the Symbiot PTFE-covered stent to reduce distal embolization during percutaneous coronary intervention in saphenous vein grafts. J Invasive Cardiol. 2005;17:609-612.
20. Stankovic G, Colombo A, Presbitero P, van den Branden F, Inglese L, Cemigliaro C, Niccoli L, Bartorelli AL, Rubartelli P, Reifart N, Heyndrickx GR, Saunamaki K, Morice MC, Sgura FA, Di Mario C; Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts investigators. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: the Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) Trial. Circulation. 2003;108:37-42.
21. Resnic FS, Wainstein M, Lee MK, Behrendt D, Wainstein RV, Ohno-Machado L, Kirshenbaum JM, Rogers CD, Popma JJ, Piana R. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart Journal. 2003;145:42-46.
22. Jonas M, Stone GW, Mehran R, Hermiller J, Feldman R, Herrmann HC, Cox DA, Kuntz RE, Popma JJ, Rogers C; FilterWire EX Randomized Evalulation (FIRE) Investigators. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection. Eur Heart J. 2006;27:920-928.
23. Kuntz RE, Gibson CM, Nobuyoshi M, Baim DS. Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol. 1993;21:15-25.
24. O'Malley AJ, Normand SL, Kuntz RE. Application of models for multivariate mixed outcomes to medical device trials: coronary artery stenting. Stat Med. 2003;22:313-336.
25. Henry M, Henry I, Klonaris C, Polydorou A, Rath P, Lakshmi G, Rajacopal S, Hugel M. Renal angioplasty and stenting under protection: the way for the future? Catheter Cardiovasc Interv. 2003;60:299-312.